HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hochhaus, G. Search for Related Content PubMed PubMed Citation Articles by Hochhaus, G.

New Developments in Corticosteroids

Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, Florida

Correspondence and requests for reprints should be addressed to Günther Hochhaus, Ph.D., Department of Pharmaceutics, College of Pharmacy, University of Florida, Box 100494, Gainesville, FL 32610. E-mail: Hochhaus{at}UFL.edu

The goal of inhaled corticosteroid therapy is the targeted delivery of drug into the lung to achieve distinct pulmonary effects with reduced systemic side effects. Pharmacokinetic/pharmacodynamic assessment of pulmonary delivery suggests that an ideal inhaled corticosteroid and/or its delivery system should have the following characteristics: high pulmonary deposition efficiency, low oral bioavailability, high systemic clearance, optimized pulmonary residence time, and selective binding to the glucocorticoid receptor. Therefore, future developments will focus on improved delivery devices with higher pulmonary deposition; drugs or drug formulations providing prolonged pulmonary residence time (e.g., use of liposomes, microspheres, and nanothin coatings, or use of biological systems that achieve prolonged pulmonary residence time by ester formation and reactivation); drugs with efficient systemic clearance (e.g., soft drugs/hydrolyzable drugs); and/or improved pharmacodynamic selectivity.

Key Words: oral bioavailability • protein binding • pulmonary deposition • pulmonary residence time • systemic clearance

This article has been cited by other articles:

				K. Wu, A. L. Blomgren, K. Ekholm, B. Weber, S. Edsbaecker, and G. Hochhaus Budesonide and Ciclesonide: Effect of Tissue Binding on Pulmonary Receptor Binding Drug Metab. Dispos., July 1, 2009; 37(7): 1421 - 1426. [Abstract] [Full Text] [PDF]

				H. Derendorf Pharmacokinetic and Pharmacodynamic Properties of Inhaled Ciclesonide J. Clin. Pharmacol., June 1, 2007; 47(6): 782 - 789. [Abstract] [Full Text] [PDF]